Cargando…

Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis

AIM: To compare the efficacy and safety of tyrosine kinase inhibitors (TKIs) as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with positive EGFR mutation. MATERIALS & METHODS: Following a systematic literature review until December 2019,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alanazi, Abdullah, Yunusa, Ismaeel, Elenizi, Khaled, Alzarea, Abdulaziz I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2020
Materias:	Meta-Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724735/ https://www.ncbi.nlm.nih.gov/pubmed/33318755 http://dx.doi.org/10.2217/lmt-2020-0011

Ejemplares similares

Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis
por: De Mello, Ramon Andrade, et al.
Publicado: (2017)

Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy
por: Wu, Di, et al.
Publicado: (2017)

Systematic Review and Meta-Analysis of Multitargeted Tyrosine Kinase Inhibitors in Patients With Intractable Metastatic Colorectal Cancer
por: Gao, Zhenzhen, et al.
Publicado: (2020)

Risk of venous and arterial thromboembolic events associated with tyrosine kinase inhibitors in advanced thyroid cancer: a meta-analysis and systematic review
por: Bai, Yang, et al.
Publicado: (2018)

Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies
por: Tchelebi, Leila T, et al.
Publicado: (2021)

A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors
por: Forsythe, Anna, et al.
Publicado: (2020)

Comparison of direct sequencing and amplification refractory mutation system for detecting epidermal growth factor receptor mutation in non-small-cell lung cancer patients: a systematic review and meta-analysis
por: Feng, Qi, et al.
Publicado: (2017)

Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis
por: Weng, Chenghua, et al.
Publicado: (2021)

Can peripheral blood be used as surrogate in detecting epidermal growth factor receptor mutation status in advanced non-small cell lung cancer patients? A meta-analysis
por: Mao, Xiaowei, et al.
Publicado: (2017)

Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis
por: Zhu, Yixiang, et al.
Publicado: (2023)

Impact of epidermal growth factor receptor sensitizing mutations on outcomes of patients with non-small cell lung cancer treated with definitive thoracic radiation therapy: a systematic review and meta-analysis
por: Soon, Yu Yang, et al.
Publicado: (2017)

First-line therapeutic strategy for patients with advanced non–small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis
por: Chen, Chongxiang, et al.
Publicado: (2022)

Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Liu, Bing, et al.
Publicado: (2017)

Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis
por: Cavanna, Luigi, et al.
Publicado: (2019)

Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
por: Chen, Shanshan, et al.
Publicado: (2022)

Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis
por: Li, Huijuan, et al.
Publicado: (2023)

Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis
por: Li, Yan, et al.
Publicado: (2023)

Efficacy and Safety of Antiplatelet Therapy Plus Xa Factor Inhibitors in Patients with Coronary Heart Disease: A Meta-Analysis
por: Chen, Hongsen, et al.
Publicado: (2019)

Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis
por: Qian, Da, et al.
Publicado: (2023)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
por: Park, Sojung, et al.
Publicado: (2021)

Comparative efficacy and safety of oral P2Y(12) inhibitors after non-ST-elevation acute coronary syndromes: a network meta-analysis
por: Farmakis, Ioannis T, et al.
Publicado: (2022)

A comparison of efficacy and safety of potassium‐competitive acid blocker and proton pump inhibitor in gastric acid‐related diseases: A systematic review and meta‐analysis
por: Simadibrata, Daniel Martin, et al.
Publicado: (2022)

Association Between Protein Tyrosine Phosphatase Non-Receptor Type 22 (PTPN22) Polymorphisms and Risk of Ankylosing Spondylitis: A Meta-analysis
por: Meng, Xiantao, et al.
Publicado: (2017)

MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

Safety and efficiency of flow diverters for treating small intracranial aneurysms: A systematic review and meta-analysis
por: Yao, Xiyang, et al.
Publicado: (2017)

The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations
por: Feng, Yongdong, et al.
Publicado: (2021)

A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer
por: Soh, Sheila X., et al.
Publicado: (2017)

Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis
por: Wenfan, Fu, et al.
Publicado: (2023)

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer
por: Costa, Rubens Barros, et al.
Publicado: (2018)

Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors
por: Li, Nijiao, et al.
Publicado: (2023)

Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review
por: Kim, Bum Jun, et al.
Publicado: (2017)

The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis
por: Han, Shiqian, et al.
Publicado: (2017)

Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis
por: Kim, Jung Han, et al.
Publicado: (2017)

Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations
por: Masago, Katsuhiro, et al.
Publicado: (2015)

Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations
por: Zhang, Yan, et al.
Publicado: (2017)

Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors
por: Lin, Liping, et al.
Publicado: (2017)

Safety and Efficacy of Tranexamic Acid in Total Knee Arthroplasty
por: Yu, Xiao, et al.
Publicado: (2015)

EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non–Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials
por: Conforti, Fabio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_47k3hr6qtv2a1nh5gj1ijk7ef6